2024 Bang yj et al. lancet 2010 376: 687-697

Bang yj et al. lancet 2010 376: 687-697

Author: ibke

August undefined, 2024

웹2024년 9월 11일 · Adding pertuzumab to trastuzumab and chemotherapy did not significantly improve overall survival in patients with HER2-positive metastatic gastric or gastro-oesophageal junction cancer compared with placebo. Further studies are needed to identify improved first-line treatment options in these types of cancer and to identify patients with … 웹2024년 6월 5일 · Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010;376:1302]. Lancet. …

The Lancet, 18 September 2010, Volume 376, Issue 9745, Pages …

웹2024년 4월 11일 · Although recent decades have witnessed incremental improvements in the treatment of gastroesophageal junction (GEJ) carcinoma, outcomes remain modest. For … 웹2010년 11월 20일 · Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-697. View in … helpatmyonlineservicing.com

Gastric Cancer Treatment Regimens - Cancer Therapy Advisor

웹Lancet 376:687–697 CrossRefPubMed Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. 웹2012년 1월 28일 · X Paoletti, K Oba, T Burzykowski, et al., the GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) ... YJ Bang, E … 웹Dieser Übersichtsartikel stellt neue Ansätze für eine medikamentöse Therapie des Magenkarzinoms dar. Eine neu entwickelte molekulare Klassifikation des Magenkarzinoms basiert auf der Histologie, genetischen, epigenetischen und proteomischen … helpatthepoles.com

Moderne Konzepte der Systemtherapie zur adjuvanten und …

Urothelkarzinom Das Urachuskarzinom – aktuelle Konzepte einer …

웹2011년 1월 10일 · Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction … 웹2024년 2월 16일 · Gastric cancer is not a top-10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern and Western countries add to the complexity of identifying standard-of-care therapy based on international trials. help yourself with the food웹Lancet 376(9742):687–697 CrossRefPubMed Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. helpclandml

"웹2024년 6월 28일 · randomized controlled trial in 2010 (Trastuzumab for Gastric Cancer ... Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy ... gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376(9742):687-697. 7. Hofmann . M, Stoss O ... " - Bang yj et al. lancet 2010 376: 687-697

Bang yj et al. lancet 2010 376: 687-697

Trastuzumab in combination with chemotherapy versus …

웹20시간 전 · 张群综述李多杰审校. pd-1/pd-l1在食管鳞癌中的研究进展. 张群1综述李多杰2审校. 食管癌的发病率和死亡率均较高，也是最难治疗和治愈的恶性肿瘤之一。当前，免疫检查点抑制剂在肿瘤治疗中取得了突破进展，相关研究已成为热点，针对免疫检查点“程序性死亡分子1”(pd-1)及其配体pd-l1抗体的 ... 웹2024년 3월 23일 · Bang YJ ; Van Cutsem E ; Feyereislova A ; et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer ... Lancet. 2010; 376: 687-697. Summary; Full Text; Full Text PDF; PubMed; Scopus (5240) Google Scholar;

Did you know?

웹2024년 11월 12일 · DISCLOSURES: Paulo Tarantino reports personal fees from AstraZeneca outside the submitted work. Roberto Carmagnani Pestana reports consulting fees from Bayer and honoraria from Pfizer, Merck, Bayer, and Servier outside the submitted work. Shanu Modi reports grants and nonfinancial support from Daiichi-Sankyo, Genentech, Novartis, Synta … 웹2010년 8월 28일 · The Lancet. Volume 376, Issue 9742, 28 August–3 September 2010, Pages 687-697. Articles. Trastuzumab in combination with chemotherapy versus …

웹Lancet 376:687–697 CrossRefPubMed Bang YJ, Van CE, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687–697 CrossRef PubMed 웹2024년 9월 16일 · 1 Bang YJ, et al., Lancet. 2010; 376 (9742): 687-697.. 2 Janjigian YY, et al., J Clin Oncol. 2024; 39 (suppl 15): 4013.

웹Bang, Yung Jue ; Van Cutsem, Eric ; Feyereislova, Andrea et al. / Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive … 웹2015년 5월 5일 · Cochrane Database Syst Rev. 2010;(3):CD004064. 18. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. …

웹2012년 11월 19일 · www.thelancet.com Vol 376 August 28, 2010 687 Lancet 2010; 376: 687–97 This online publication has been corrected. The corrected version ﬁ rst appeared …

웹Lancet. 2010;376(9742):687–97. CrossRefPubMed Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. CrossRef PubMed helpasherpa웹2010년 8월 28일 · Request PDF Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATITrastuzumab ... helpbltechnical.com웹2010년 8월 28일 · Background: Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in … helpathomeoxfordhealthcare웹2016년 5월 3일 · Bang YJ ; Van Cutsem E ; Feyereislova A ; et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive … helpdesl.shsconsultores웹2010년 11월 20일 · Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a … helpatwalmart.com웹Methods/Design: This single-center study was designed to combine low-dose apatinib with camrelizumab plus the SOX regimen in diagnosed potentially resectable and initially unresectable AGC/GEJC. This a prospective, open-label, single-arm, dose escalation and extension phase Ib clinical trial, conducted in Jiangsu Province Hospital, beginning ... helpclubessentials.com웹Bang YJ, Van Cutsem E, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet . 2010;376(9749):1302]. helpcookcountyhealth.org